InterBioTech
FT-XLS250
Entecavir
Product Description
Catalog #:
XLS250, 5mg XLS251, 10mg XLS252, 50mg XLS253, 100mg
AXAIV0, 1ml 10mM in DMSO.
Catalog #: Name:
Entecavir, Monohydrate
Syn: BMS200475 monohydrate; SQ34676 monohydrate
CAS : 209216-23-9
MW :
295.29
Formula : Properties:
C12H17N5O4
DMSO : ≥ 50 mg/mL (169.33 mM)
H2O : 2.8 mg/mL (9.48 mM) >99.5%
Also available:
Storage:
Powder: -20°C (longterm; possible at +4°C (2 years)(M) In solvent: -80°C (6 months) -20°C (1 month)
Entecavir free form #RO893P/Q/R
(Syn.:BMS200475;SQ34676)
CAS No. : 142217-69-4; MW: 277.2 For Research Use Only
Introduction
Entecavir monohydrate(BMS200475 monohydrate; SQ34676 monohydrate)is a potent andselective inhibitorof HBV, with an EC50 of 3.75 nM in HepG2 cell.
IC50 & Target EC50:3.75 nM (anti-HBV, HepG2 cell)[1]
In Vitro
*Solubility :
DMSO : ≥ 50 mg/mL (169.33 mM)
H2O : 2.8 mg/mL (9.48 mM; Need ultrasonicandwarming)
*Preparation : 1mM = 1mg in 3.3865 mL
Entecavir monohydrate(BMS200475 monohydrate; SQ34676 monohydrate)has a EC50 of 3.75 nM againstHBV. It is incorporated intothe proteinprimer of HBV and subsequently inhibits theprimingstepof the reverse transcriptase. The antiviral activity of BMS-200475 is significantlyless against theother RNA and DNA viruses[1]. Entecavir monohydrateis more readilyphosphorylatedto its active metabolites than otherdeoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h[2].
P.1
InterBioTech
FT-XLS250
In Vivo
*Preparation : 1. Add each solventone by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 3 mg/mL (10.16 mM); Clear solution
2. Add each solventone by one: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3 mg/mL (10.16 mM); Clear solution
3. Add each solventone by one: 10% DMSO 90% corn oil
Solubility: ≥ 3 mg/mL (10.16 mM); Clear solution
Daily oral treatmentwith Entecavir monohydrateat doses rangingfrom 0.02to 0.5 mg/kgof body weightfor 1 to 3 months effectively reduces thelevel of woodchuck hepatitisvirus (WHV) viremia in chronicallyinfected woodchucks[3].
References
[1]. Innaimo SF, et al. Identification of?BMS-200475?as a potent and selective inhibitor of hepatitisB virus. Antimicrob Agents Chemother.1997 Jul;41(7):1444-8.
[2]. Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin.?2005 Nov;21(1 1):1845-56. [3]. Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside?BMS-200475?in the woodchuck modelof hepatitisB virus infection. Antimicrob Agents Chemother.?1998 Dec;42(12):3209-17.
- More:
- •Mol Pharm. 2018 Oct 30.
•Virus Res. 2019 Jul 31:197677.
Relatedproducts
Related Small Molecules: antiviral compounds
Vesatolimod #WPY994 (CAS :1228585-88-3 ; MW : 410.5) Bay 41-4109 (Bayer 41-4109) #AX5V71 (CAS :298708-81-3; MW:395.76) 4,5-Dicaffeoylquinicacid (Isochlorogenic acid C) #1M8596 (CAS : 57378-72-0; MW :516.4) Morphothiadin (GLS4) #AYHNG1 (CAS : 1092970-12-1; MW : 509.39) AB-423 #B2VBA1 (CAS : 1572510-80-5; MW ; 386.39) Squalamine (MSI-1256)#PM9151 (CAS : 148717-90-2; MW : 627.96)
Ordering information
Catalogsize quantities andpricesmay be found at http://www.interchim.com. Please inquirefor higherquantities(availability, shipmentconditions). Please contact InterBioTech – Interchim for anyother information
Hotline : +33(0)4 70 03 73 06 – [email protected]
Disclaimer : Materials are sold for research use only, and are not intended for food,drug, household,or cosmetic use. Interchim® is not liable for any damage resulting from handling or contact with this product.
S01E
P.2